Halozyme Therapeutics HALO Acquired in-process research and development expenses

Acquired in-process research and development expenses at other companies

Halozyme TherapeuticsHALO

$71.22M—

Gilead SciencesGILD

$107M-57.7%

Campbell SoupCPB

$6M-82.9%

AccentureACN

$204.33M-29.0%

Gen Digital Inc.GEN

$10M—

Regeneron PharmaceuticalsREGN

$101.9M+728%

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's acquired in-process research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's acquired in-process research and development expenses?: Halozyme Therapeutics (HALO) reported acquired in-process research and development expenses of $71.22M in Q4 2025.
What does acquired in-process research and development expenses mean?: This metric captures the costs associated with acquiring in-process research and development (IPR&D) projects from third parties. Unlike internal R&D, these costs are often one-time payments related to business combinations or licensing deals. It reflects the company's strategy of buying innovation rather than developing it entirely in-house.